Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study

High-risk myeloid malignancies, particularly those associated with adverse cytogenetic and molecular characteristics, present a challenging therapeutic scenario. The increased prevalence of these diseases in older individuals, who often have comorbidities or are considered frail, their aggressive nature, and poor survival rates even after allogeneic hematopoietic cell transplantation (HCT), demand innovative approaches.1 Traditional myeloablative conditioning (MAC), typically based on total body irradiation (TBI) or high-dose busulfan, has been associated with significant organ toxicity and high non-relapse mortality (NRM).

Source: Biology of Blood and Marrow Transplantation - April 20, 2024 Category: Hematology Authors: Ivan Pasic, Tommy Alfaro Moya, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson Source Type: research